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ABSTRACT
EVALUATION OF DRUG-LOADED GOLD NANOPARTICLE CYTOTOXICITY AS
A FUNCTION OF TUMOR TISSUE HETEROGENEITY
Hunter A. Miller
July 11, 2018
The inherent heterogeneity of tumor tissue presents a major challenge to nanoparticlemedicated drug delivery. This heterogeneity spans from the molecular to the cellular (cell
types) and to the tissue (vasculature, extra-cellular matrix) scales. Here we employ
computational modeling to evaluate therapeutic response as a function of vascularinduced tumor tissue heterogeneity. Using data with three-layered gold nanoparticles
loaded with cisplatin, nanotherapy is simulated with different levels of tissue
heterogeneity, and the treatment response is measured in terms of tumor regression. The
results show that tumor vascular density non-trivially influences the nanoparticle uptake
and washout, and the associated tissue response. The drug strength affects the proportion
of proliferating, hypoxic, and necrotic tissue fractions, which in turn dynamically affect
and are affected by the vascular density. This study establishes a first step towards a more
systematic methodology to assess the effect of vascular-induced tumor tissue
heterogeneity on the response to nanotherapy.
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INTRODUCTION

Although nanoparticle-mediated drug delivery offers the promise of more targeted
and effective treatment of cancer, few of the myriad of formulations evaluated in the
laboratory have reached clinical application. Major hurdles have included concerns about
toxicity, lower than expected efficacy, and off-target effects (Miele, Spinelli et al. 2012).
In particular, the tumor microenvironment can present a formidable barrier that hinders the
transport of drug molecules as well as nano-sized vehicles (Primeau, Rendon et al. 2005,
Hait and Hambley 2009, Warren 2013). In order to be effective, nanoparticle-mediated
drug delivery needs to utilize the vascular network to preferentially reach the tumor site
and penetrate into the cancerous tissue to establish cytotoxic concentrations, avoid uptake
by the reticulo-endothelial system (RES), diffuse through the extra-cellular matrix (ECM)
mesh of proteins, remain close or be uptaken by the cancer cells, and efficiently release the
payload of drug molecules to achieve cytotoxicity. To address these requirements and
increase the efficacy of chemotherapy, nanoparticles can be functionalized with various
compounds to help reduce systemic distribution and avoid intrinsic cellular resistance
mechanisms (Koziara, Whisman et al. 2006, Bertrand, Wu et al. 2014). Yet uncoordinated
angiogenic stimuli by proliferating and hypoxic cancer cells induce a heterogeneous
vascular response, characterized by tortuous vessels with abnormal structure
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and irregular flow (Izuishi, Kato et al. 2000, Minchinton and Tannock 2006). The
inadequacy of the vascular network promotes intra-tumoral tissue regions with
heterogeneous proliferative, hypoxic, and apoptotic states, while severely impairing the
transport of and the response to systematically-administered drugs and nanoparticles.
The efficacy of nanoparticles in cancer treatment is typically evaluated with in vitro
and in vivo experimental models, which are indispensable for pre-clinical evaluation.
However, in vitro models lack key features of cancerous tissue found in vivo, including a
vascular network, while in vivo models present challenges due to systemic interactions
which may not be necessarily easily teased apart. As a complement to these experimental
venues, computational simulation of cancer nanotherapy has aimed to provide the
capability for system-level analysis (Frieboes, Sinek et al. 2006, Decuzzi, Pasqualini et al.
2009, Godin, Driessen et al. 2010, Li, Al-Jamal et al. 2010, Li and Reineke 2011, Li, Panagi
et al. 2012, van de Ven, Wu et al. 2012, Gao, Li et al. 2013, Kaddi, Phan et al. 2013, Li,
Czyszczon et al. 2013, van de Ven, Abdollahi et al. 2013, Wu, Frieboes et al. 2014). In
particular, we have recently studied via mathematical modeling the extravasation, uptake,
and distribution of nanoparticles subject to heterogeneous tumor tissue and vascular
conditions (Curtis, England et al. 2016, Curtis, Rychahou et al. 2016, Reichel, Curtis et al.
2017).
The distribution and penetration of 2- and 3-layered gold nanoparticles were
recently evaluated in vitro (England, Priest et al. 2013) and in vivo (England 2015). The
purpose of these nanoparticles was to increase chemotherapy efficacy (England 2015,
England, Gobin et al. 2015) via enhanced distribution and penetration into tumor tissue.
The 3-layer gold nanoparticles were functionalized with phosphatidylcholine,
2

hexadecanethiol and high-density lipoprotein (England, Priest et al. 2013). Computational
modeling was implemented (Curtis, England et al. 2016) to simulate the performance of
these nanoparticles in vivo given measurements in vitro, with the goal to begin bridging
the gap from the pre-clinical to the clinical setting. The model parameters were set from
experimental measurements with 2D and 3D cultures of A549, H358, and PC9 Non-Small
Cell Lung Cancer (NSCLC) cells (England, Priest et al. 2013, England 2015).
In this study, computational simulation is employed to evaluate the role of vascular
density-induced heterogeneity on the distribution of 3-layered gold nanoparticles in tumor
tissue and the associated drug release. Small metastatic lesions are simulated in a well
vascularized organ, such as the lung, and cisplatin is used as the model drug. The
nanoparticle effectiveness is analyzed by calculating fractions of control for tumors of
various blood vessel densities after bolus administration of the drug loaded nanoparticles.
Tumor therapy is simulated with various drug inhibitory concentrations calibrated to
achieve a 50% reduction in tumor size (IC50) at four timepoints (24hr, 48hr, 72hr, 96hr)
post treatment initiation. This work represents a first step towards quantifying tumor
response to drug-loaded nanoparticles based on vascular-network induced tissue
heterogeneity.
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MATERIALS AND METHODS

Nanoparticle Synthesis and Characterization
Three-layered nanoparticles were previously created in (England, Priest et al.
2013).

Briefly, citrate-stabilized gold nanoparticles were synthesized by reducing

chloroauric acid with trisodium citrate (Frens 1973). The first layer applied was 1Hexadecanethiol (TL), followed by phosphatidylcholine (PC), and then HDL.
Nanoparticles were characterized via extinction spectra using ultraviolet-visible (UV-Vis)
spectrometry, zeta potential measurements, DLS (dynamic light scattering) to determine
hydrodynamic size (intensity distribution) in solution, determination of shape and size with
scanning electron microscopy, and confirmation of presence of lipids on the particle cores
using a Fourier transform infrared (FTIR) instrument. Cisplatin (7.5 mg) was then added
to the nanoparticles in solution and allowed to react for 2 h (England, Priest et al. 2013).
Experimental Cytotoxicity Data
As described in (England, Priest et al. 2013), A-549 cells were maintained in
standard culture conditions, and used to form tumor spheroids.

Cytotoxicity was first

measured in 3D cell culture with free drug at varying concentrations (1024, 256, 64, 16, 4,
1, 0.25, 0.0625 µM) for 48 h. The spheroids were exposed to varying concentrations of
drug-loaded nanoparticles calculated by considering two parameters: (1) the loading
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efficiency from HPLC data showing the exact concentration of drug encapsulated onto the
nanoparticles (England 2015) and (2) the percent of drug released over the 48-hour period.
Computational Modeling
1. Tumor Growth
The tumor growth component is based on (Macklin, McDougall et al. 2009, Wu,
Frieboes et al. 2013), in which tumor tissue is denoted by  and its boundary by  . Tumor
tissue is divided into three regions: a proliferating region where cells have sufficient
oxygen and nutrients to proliferate, a hypoxic region where cells have sufficient oxygen
and nutrients to survive but insufficient for proliferation, and a necrotic region where cells
lack sufficient oxygen and nutrients for survival. The non-dimensionalized tumor growth
velocity follows Darcy’s Law [48]:
[Equation 1]
where μ is cell-mobility, P is oncotic pressure, χE is haptotaxis, and E is the density of the
extracellular matrix (ECM). Refer to (Macklin, McDougall et al. 2009) for a more detailed
description of E and χE. The overall tumor growth can be associated with the rate of volume
change by assuming that the cell density within the proliferating region remains constant:
[Equation 2]
where

p

is the non-dimensionalized net proliferation rate (described below).

2. Angiogenesis
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The angiogenesis component is based on (McDougall, Anderson et al. 2006) to
represent blood flow, vascular leakage and vascular network remodeling resulting from
wall shear stress and mechanical stress imposed by the tumor tissue as it changes in time.
Briefly, as the tumor grows within a vascularized environment, the tissue has access to
oxygen and nutrients diffusing from the vasculature. The interstitial flow of oxygen and
nutrients is influenced by tissue pressure and by distance from the nearest vessel. Refer to
(Macklin, McDougall et al. 2009, Wu, Frieboes et al. 2013) for a more detailed description
of the angiogenesis model.
3. Transport of oxygen and nutrients
Oxygen and nutrients σ are transported to the tumor from the location of extravasation
from the vasculature. The extravasation rates



  =  pre
ev = neo
and ev
represent the rate

that σ are supplied from the neo- and pre-existing vasculature, respectively.

These

substances, which diffuse with a coefficient Dσ, are taken up by both host tissue cells and
tumor cells with rates


tissue


, tumor , and qs and decay with rate N in the necrotic region.

Under steady-state conditions, the formulation of oxygen and nutrient uptake and decay is
(Macklin, McDougall et al. 2009, van de Ven, Wu et al. 2012, Wu, Frieboes et al. 2014):

0 =   ( D  ) + ev (x, t , 1vessel , pi ,  , h) −   ( )

[Equation 3]

where x is position, t is time, 1vessel is the characteristic function for the vasculature (equals
1 at vessel locations and 0 otherwise), pi is interstitial pressure, and h is the hematocrit in
the vascular network [48]. Extravasation is modulated by the extravascular interstitial
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pressure pi, scaled by the effective pressure pe with the weight of the convective transport
component of small molecules,


ev =  ev 1vessel (x, t )(

k pi

(van de Ven, Wu et al. 2012):

p
h
− h min ) + (1 − k pi i )(1 −  )
pe
HD

[Equation 5]

H D and hmin are constants which represent the normal and minimum hematocrit necessary


for oxygen extravasation, respectively.  ev represents the constant transfer rate from preexisting and tumor-induced vessels.
4. Transport of nanoparticles
Nanoparticle transport s through the tumor tissue is simulated from the point of
extravasation from the vasculature. The uptake rate of nanoparticles by host and tumor
s

cells is  uptake (van de Ven, Wu et al. 2012, Wu, Frieboes et al. 2014):
s
s
=   ( Ds s ) + evs (x, t , 1vessel , pi , s) −  uptake s
t

[Equation 6]

s

Under the assumption that the transfer rate  ev from both pre-existing and tumor-induced
vessels is constant, nanoparticle extravasation is: represented by (van de Ven, Wu et al.
2012, Wu, Frieboes et al. 2014):
s

evs =  ev 1vessel (x, t )(1 − k p

i

pi Cts
)(
− s)
pe C s

[Equation 7]

where diffusion of particles into the tumor tissue is modulated by the interstitial pressure
s

(van de Ven, Wu et al. 2012). Particle extravasation is assumed to be
7

Cts = C e− t

, where

s

C is the initial concentration (van de Ven, Wu et al. 2012). The extravasation of particles
is concentration dependent, simulating first order kinetics. The decay constant α is
measured from previous in vivo experiments, in which the particle half-life is estimated to
be 12 hours (England, Huang et al. 2015). The diffusivity of the particles was calibrated
from the combination of charge and size properties based on measurements obtained in
vitro (England, Priest et al. 2013).
5. Transport of drug
Drug G is released at the point of extravasated particles and diffuses through the tumor
G

tissue with the coefficient DG. The rate  decay combines the effects of drug uptake by tumor
and normal cells and the wash-out from the interstitial space, and reflects the half-life of
the drug (Curtis, England et al. 2016):
G
G
G
=   ( DG G ) + release
(t , s ) −  decay G
t

The drug release

[Equation 8]

G
release
from the particles is represented by (Curtis, England et al. 2016):

G
release
= sCtG

CtG

[Equation 9]

is the release of drug which is fitted in time to follow the results obtained from in vitro

experiments in [38]. The drug release rate thus combines the effect of particle concentration
B
=0
and drug release profile. All diffusion equations have the boundary condition n

where B is the diffusible substance.
6. Drug effect on tumor
8

Cisplatin is a cell cycle dependent drug, and thus its cytotoxic effect is only exerted on
proliferating cells. Drug effect is included into the proliferation term

p

where  effect is the

rate of drug-induced cell death (Wu, Frieboes et al. 2014):
0

  (1 −  effect G ) − A
p =  M
0
 −G
 N

outside the tumor
in proliferating tissue
in hypoxic tissue
in necrotic tissue

[Equation 10]

where λA is the apoptosis rate, λM is the mitosis rate, and GN is the non-dimensional rate of
volume loss in the necrotic tumor core (it is assumed that cellular debris is constantly
degraded and the fluid is removed (Wu, Frieboes et al. 2014)). This pharmacodynamic
model assumes that cell proliferation and apoptosis rates are similar before and after drug
therapy. Cell death is assumed to be instantaneous.
7. Calibration of Rate of Drug-Induced Cell Death
The model parameters for oxygen, drug effect and tumor growth were calibrated
using data obtained experimentally with NSCLC tumor spheroids to find an 48hr IC50 for
simulated avascular spheroids (in vitro simulations) (England, Priest et al. 2013). A
detailed description of the in vitro experiments used to calibrate the simulations can be
found in (Curtis, England et al. 2016), which includes the synthesis, functionalization,
characterization, drug loading, and drug release of the nanoparticles and cytotoxicity
experiments in 2D and 3D cell culture. Since the concentration of NP’s and drug were not
changed among the four IC50’s, the free drug concentration after 48 h of exposure was
calculated based on the data from our previous study (Curtis, England et al. 2016). Then,
the 24hr, 72hr, and 96hr IC50 avascular treatment drug concentrations were scaled by the
9

same proportion as the change in drug effect. The trapezoid method was used to calculate
the corresponding AUC’s to quantify the avascular IC50’s.
8. Tumor Tissue Heterogeneity
The values for drug-induced cell death used for the avascular IC50’s were
employed in therapy simulations with vascularized lesions (simulations of in vivo
condition). To link the differences in drug effect to the effects of heterogeneous
vascularization density, the in vivo simulations used the same nanoparticle concentration
in a bolus dose as was needed in the in vitro simulations to achieve the IC50. All tumors
grown in host tissue with the same pre-existing vessel densities but different oxygen
thresholds for hypoxia and necrosis were grown to the same initial radius of 0.56mm. In
vivo simulations were run for a sufficient amount of time to obtain the smallest tumor radii
following NP bolus injection and were used to compare the efficacy of cisplatin-loaded
nanoparticles among the various cases. The tumor blood vessel density was calculated by
dividing vessel surface area (vessel length x vessel cross sectional area) by the tumor area.
The main tumor, nanoparticle, and drug parameters and their values are summarized in
Table 1.
Parameter

Value

Reference

Tumor proliferation rate

1 day-1

Measured

in

(Curtis,

England et al. 2016)
Oxygen diffusivity

1 (*)

(Wu, Frieboes et al. 2013)

Oxygen transfer rate from vasculature

5 (*)

(Wu, Frieboes et al. 2013)
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Oxygen uptake rate by proliferating 1.5 (*)

(Wu, Frieboes et al. 2013)

tumor cells
Oxygen uptake rate by hypoxic tumor 1.3 (*)

(Wu, Frieboes et al. 2013)

cells
Oxygen

uptake

rate

by

tumor 0.12 (*)

(Wu, Frieboes et al. 2013)

0.35 (*)

(Wu, Frieboes et al. 2013)

microenvironment
Oxygen decay rate

NP extravasation from angiogenic vs. 10

Estimated

normal vessels
NP diffusivity

0.3 (*)

(England, Priest et al. 2013)

NP decay

12hr half-life

Estimated

CDDP diffusivity

0.6 (*)

Estimated

CDDP drug effect

27, 9.45, 5.6, Calibrated to experimental
4.0

data

(for 24, 48, 72,
and 96 h IC50)
CDDP decay rate

0.5hr half-life

CDDP release profile from NP

(Leighl 2012)
Measured
2015)
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in

(England

CDDP in vitro IC50 (48 h) for A549 15.9 ± 1.2 μM

Measured

in

(Curtis,

cells (spheroid)

England et al. 2016)

Table 1: Computational model main parameters and associated values. All other model
parameters are as in (Wu, Frieboes et al. 2013). (*) Value is rescaled by the square of the
simulation system characteristic length (1 cm) and divided by the system characteristic
time (1 sec) multiplied by the oxygen diffusivity (Nugent and Jain 1984) (1 x 10-5 cm2 s-1).
CDDP: cisplatin; NP: 3-layered gold nanoparticles characterized in (England, Priest et al.
2013, England 2015, Curtis, England et al. 2016).
Four levels of tissue heterogeneity were obtained, respectively labeled “very low,”
“low,” “medium,” and “high,” by varying the angiogenesis-induced tissue vascularization
based on the response to tumor angiogenic factors (TAF) that were in proportion to the
tumor tissue hypoxic and necrotic levels. The values for these levels are defined in Table
2. The hypoxic threshold defines the oxygen level at which tissue becomes hypoxic
(quiescent but still viable) and ceases to proliferate, while the necrotic thresholds defines
the oxygen level at which the tissue becomes necrotic (dead).

Level of Tissue Heterogeneity

Tumor hypoxic threshold

Tumor necrotic threshold

VERY LOW

0.305

0.300

LOW

0.405

0.400

MEDIUM

0.485

0.480

HIGH

0.575

0.570

12

Table 2: Definition of levels of tumor tissue heterogeneity based on the thresholds for
inducing hypoxia and necrosis. The values for HIGH are based on the previously calibrated
tumors simulated in (van de Ven, Wu et al. 2012, Curtis, England et al. 2016).
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RESULTS

Experimental data
The 3-layer gold nanoparticles were previously characterized as having a maximum
wavelength of 5.35 nm, a hydrodynamic diameter of 80.2 ± 12.4 nm, and a zeta potential
of -6 mV (Curtis, England et al. 2016). The cisplatin loading efficiency was 78.9 ± 0.7%
(Curtis, England et al. 2016). The nanoparticles released 59.1 ± 2.0% of drug within the
first 3 hours, 76.7 ± 1.84 within 48 h, and 78.9 ± 2.1) by 96 h (England 2015).
Simulation of heterogeneous tumor growth
Tumors were first grown under the conditions of VERY LOW, LOW, MEDIUM
and HIGH heterogeneity as defined in Table 2 to the same radius (0.566 mm) before
treatment. The simulated tumors during the initial growth phase are shown in Figure 1.
Depending on the level of heterogeneity, this growth took varying amounts of time, with
the HIGH case taking the longest (22.7 simulated days). The tissue heterogeneity is
characterized in Figure 2 as a function of the tumor radius. While the intra-tumoral vessel
density initially increased for the VERY LOW and LOW cases, it plateaued for radii
beyond 0.40 mm (Figure 2A). In contrast, the density for MEDIUM and HIGH conditions
decreased for radii below 0.31 and 0.28 μm, respectively, before becoming larger. The
proliferative tissue fraction corresponding to these vascular densities indicates that for a
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radius of 0. 566 mm right before start of treatment, these fractions were being maintained
at 96, 82, 68, and 55% for VERY LOW, LOW, MEDIUM and HIGH conditions,
respectively (Figure 2B). At this radius, the hypoxic tissue fractions were correspondingly
lower, at 2.4, 4.8, 10.0, and 20.2% (Figure 2C), while the necrotic fraction values were
1.2, 12.6, 21.9, and 25.3%, respectively. Compared to the more stable values maintained
for the proliferating and hypoxic as the tumor radius increased, the necrotic fractions
(Figure 2D) (except for the VERY LOW condition) exhibited an initial steep increase
followed by a gentle decline past 0.350 μm as the proliferating portion slowly started
gaining in value.

15

Figure 1. Simulation of tumor nodules growing in time with different levels of vascularinduced tissue heterogeneity. Red color denotes the proliferating region, blue indicates
hypoxia, and brown means necrosis.

The pre-existing capillary grid is shown as

rectangular lines along with irregular sprouts growing from them due to the angiogenesis
process. Bar: 250 μm.
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Figure 2. Characterization of tumor tissue heterogeneity. (A) Intra-tumoral vascular
density; (B) Proliferating fraction; (C) Hypoxic fraction; (D) Necrotic fraction.

Calibration of drug effect
A simulated tumor growing in the dish in vitro, surrounded by plentiful oxygen and
nutrients, is shown in Figure 3A. This tumor was exposed after 30 d to drug in silico for
48 h to determine the value for the drug effect  effect to achieve a 50% reduction in tumor
size (the “IC50”) (Figure 3B). This value was then assigned the units of the drug
concentration to achieve the same regression with the tumor spheroids in the experiments
in vitro (Curtis, England et al. 2016).

A range of area-under-the-curve values were

obtained, as shown in Table 3.
17

Figure 3. Simulated tumor growing in avascular conditions in vitro. Red: proliferating
tissue; blue: hypoxic tissue; brown: necrotic tissue. Bar: 250 μm.
IC50 Range of Time (h)

AUC (μM*h)

24hr IC50

1082

48hr IC50

760

72hr IC50

676

96hr IC50

644

Table 3. Area-under-curve (AUC) calculated for four different ranges of time for a
simulated tumor spheroid growing in in vitro conditions.

Simulation of nanoparticle-mediated drug delivery
Representative simulation images of vascularized tumors at the start of treatment
with the various levels of heterogeneity are shown in Figure 4. As the heterogeneity
18

increases from VERY LOW to HIGH, the penetration and spatial distribution of
nanoparticles and the drug released from them correspondingly becomes more
heterogeneous. The deepest nanoparticle penetration is achieved with the VERY LOW
case, for which the drug release is concentrated in the inner core of the tumor. In contrast,
in the HIGH case the nanoparticles become stuck in the tumor periphery, unable to
penetrate into the tissue. This is consistent with previous modeling work showing that
tumor tissue heterogeneity leads to inhomogeneous small molecular and nanoparticle
distribution, with the highest concentrations occurring on the periphery (Frieboes, Wu et
al. 2013, Curtis, Wu et al. 2015). Interestingly, although in the LOW case the nanoparticles
penetrate deeper, their concentration is more heterogeneously distributed than in the
MEDIUM case, suggesting that the relationship between heterogeneity and nanoparticle
penetration is not linear (Frieboes, Wu et al. 2013, Curtis, Wu et al. 2015).

19
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Figure 4. Representative simulation images of vascularized tumors with the various levels
of heterogeneity shown at the start of treatment with cisplatin-loaded nanoparticles. Red:
proliferating tissue; blue: hypoxic tissue; brown: necrotic tissue. Bar: 250 μm.

The nanoparticle concentration within tumor tissue for each value of the drug
strength (respectively based on 24, 48, 72, and 96 h IC50 values in vitro) is shown in Figure
5. In the case of the 24 h IC50 value, the concentrations are similar regardless of level of
tissue heterogeneity, with an initial sharp peak at 2.5 h post-treatment initiation followed
by a sharp drop to 35% of initial concentration within 4 h. The concentration then declines
slowly afterwards, to 10% of initial by 30 h. For the other three drug strengths, the LOW
case exhibits the highest concentration of nanoparticles overall, with 30% still in tissue
after 30 h. For the 48h IC50 case, the VERY LOW case retains the second highest
concentration, while for both 72 and 96 h, it is similar to the MEDIUM and HIGH
conditions, decreasing to 20% of initial value by 30 h. Noticeably, the nanoparticle
concentrations are more heterogeneous in time for the 48 and 72 h cases, while the 24 and
96 h evince more consistent profiles. This suggests that the drug strength is also a key
parameter that influences the nanoparticle concentration as the tissue responds in time to
the drug, and is consistent with recent findings from an optimization model applied to this
tumor model system (Chamseddine, Frieboes et al. 2018).
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Figure 5. Nanoparticle concentration within tumor tissue for each value of the drug
strength.

The drug release from the nanoparticles within the first 4 h for the various drug
strengths is shown in Figure 6. Consistently, the highest concentrations were achieved for
HIGH tissue heterogeneity and the lowest for the VERY LOW heterogeneity. The 24 h
IC50 strength exhibited the greatest differential between the various levels of
heterogeneity, at 7 μM for HIGH and 5 μM for VERY LOW, in contrast to the 96 h IC50,
which evinced 1 μM for HIGH and 0.75 μM for VERY LOW.
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Figure 6. Drug release from the nanoparticles within the first 4 h for the various drug
strengths.

The area-under-the-curve (AUC) for the nanoparticles within tumor tissue is shown
in Figure 7A. Whereas the AUC for the 24 h IC50 condition declined from the VERY
LOW to the HIGH heterogeneity levels, ranging from 7 to 6 %initial.h, the other three IC50
conditions had the highest values for the LOW level. At this level, the 72 h IC50
predominated overall at 17.5 %initial.h. In contrast, the highest AUC at the VERY LOW
case was attained for the 48 h IC50 at 14 %initial.hr, while the highest values for the
MEDIUM and HIGH conditions were for the 96 h IC50, at 15 and 13.8 %initial.h,
respectively.

In spite of these inhomogeneous outcomes for the nanoparticles, the

intratumoral vascular AUC for the drug released from them had a more consistent pattern
23

across the levels of heterogeneity and drug strength (Figure 7B). The 24 h IC50 evinced
the highest values overall, increasing from 9.6 μM.h to 13.1 μM.h for the VERY LOW and
HIGH levels, respectively. The values for the other drug strengths followed the same trend
but at lower values, ranging for the VERY LOW to HIGH levels at 3.5, 2.1, and 1.5 μM.h
to 4.7, 2.8, and 2.0 μM.h for 48, 72, and 96 h IC50 strengths, respectively. Thus, the 96 h
IC50 had the lowest drug AUC values.

Figure 7. Intratumoral nanoparticle and intratumoral vascular drug AUC values.

Figure 8 shows the minimum tumor radii achieved at each IC50 drug strength as a
function of the intratumoral vascular drug AUC for each level of tissue heterogeneity. In
all cases, there was a nearly linear relationship between tumor radius and AUC, with radii
decreasing as the AUC values increased. The largest radius reduction was achieved by the
VERY LOW case with the 24 h IC50 drug strength, yielding 52% from the initial tumor
radius, while the smallest decrease at this drug strength was 41% for the MEDIUM case.
On the other hand, the 96 h IC50 drug strength was equally ineffective across all levels of
heterogeneity, achieving at best a 9% reduction in tumor radius. This information is
summarized in Figure 10, highlighting the nonlinear decrease in tumor radii for the
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different drug strengths across the four levels of heterogeneity.

While higher drug

strengths, as represented by lower IC50 values, yielded higher response, the magnitude of
this response was dependent on the level of tissue heterogeneity.

Figure 8. Minimum tumor radii achieved at each IC50 drug strength as a function of the
intratumoral vascular drug AUC for each level of tissue heterogeneity. The points along
each curve represent, from left to right, 96, 72, 48, and 24 IC50-based drug strength values.

Figure 9 shows the minimum tumor radii as a function of drug strength dependent
on the size of the tumor tissue viable (proliferating and hypoxic) fraction and intratumoral
vascular density, both calculated at the start of the treatment. As expected, as the drug
strength increases (represented by the IC50 values), the tumor regression is
correspondingly higher.

For the highest strength (24 h IC50), this regression was
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maximized by higher values of the viable tumor tissue fraction (Figure 9A) and lower
values of the intratumoral vascular density, together representing lower tumor
heterogeneity (Figure 9B). For the other drug strengths, the regression was generally
independent of this density.

Figure 9. Minimum tumor radii achieved during treatment as a function of drug strength
dependent on the size of the tumor tissue viable (proliferating and hypoxic) fraction and
intratumoral vascular density, both calculated at the start of the treatment.

Figure 10. Minimum tumor radius achieved during therapy as a function of drug strength
and tissue heterogeneity.
26

DISCUSSION

This study builds upon previous experimental (England, Priest et al. 2013, England
2015) and modeling work (Curtis, England et al. 2016) to evaluate the effect of vascular
density-driven tissue heterogeneity on NSCLC tumor response to cisplatin delivered via 3layered gold nanoparticles.

As such, this work represents a first step towards the

development of a principled approach to predict nanotherapy efficacy using patient-tumorspecific characteristics, such as proliferative index and vascular density. Tumors with
different intra-tumoral vascular densities (Figure 1) were first simulated by varying the
oxygen thresholds for hypoxia and necrosis to yield different proportions of proliferating,
hypoxic and necrotic tissue (Figure 2). Next, using experimentally-obtained data with 3layered gold nanoparticles loaded with cisplatin (England, Priest et al. 2013, England
2015), the magnitude of the drug effect in silico was calibrated for inhibitory drug
concentrations to achieve 50% tumor tissue remission over 24, 48, 72, and 96 h (Figures
5, 6). The resulting inhomogeneous intratumoral nanoparticle and drug AUC values
(Figure 7) yield correspondingly heterogeneous tumor regressions (Figures 8, Figure 10).
This system was then used to determine the expected tumor size based on the fraction of
viable tumor tissue and intratumoral vascular density (Figure 9).
The results show that vascular tumor density coupled with the drug strength non-trivially
influences the nanoparticle uptake and washout, and the associated tissue response. The
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drug strength affects the proportion of proliferating, hypoxic and necrotic tissue fractions,
which in turn dynamically affect and are affected by the vascular density. A higher drug
strength may be able to achieve a stronger tumor regression but only if the intra-tumoral
vascular density is beyond a certain threshold (Figure 9B). In contrast, drug strengths of
lower magnitude may yield similar responses regardless of vascular density. Although
regression generally correlated with drug strength, the level of vascular density-driven
tissue heterogeneity is shown to modulate this regression, to the point that the difference
in drug strength may not matter (Figure 10). Since drug strength is a key clinical parameter
underlying both response and systemic toxicity, the overall results support the notion that
drug strength remains a critical modeling parameter for predictive evaluation. This is
consistent with recent modeling work that combined an optimization approach to determine
optimal nanoparticle sizes for maximum tumor regression (Chamseddine, Frieboes et al.
2018).
This study establishes a first step towards a more systematic methodology to assess
the effect of tumor tissue vascular density on the response to nanotherapy.

With

experimentally-measurable parameter values, the system could be expanded to evaluate
other types of nanoparticles and drugs. Vascular permeability and blood volume could be
quantified by positron emission tomography (Chen, Tong et al. 2017). In particular for nonsmall cell lung cancer (NSCLC), tumor parameters such as vascular density could be
measured via imaging or histological analysis (Ma, Ren et al. 2016). Additionally, there
exist numerous methods for detecting tumor hypoxia, including the detection of hypoxiainduced proteins through the HIF transcription factor (Zhong, De Marzo et al. 1999,
Brahimi-Horn and Pouyssegur 2005). The concept of manipulating the vascular density to
achieve improved response (e.g., “vascular normalization” (Jain 2001)), as has been tried
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for NSCLC with small molecule tyrosine kinase inhibitors or monoclonal antibodies that
target VEGF (Hall, Le et al. 2015), may find further utility depending on the drug strength.
Clinically, angiogenesis inhibitors have been shown to lead to improvements in overall
survival when combined with standard first line and second line therapy (Hall, Le et al.
2015). In cases where tumor vascular density is determined by the model to be inadequate
for a desired level of response, angiogenesis inhibitors may be able to change this density
to augment the nanotherapy efficacy.
The interaction between vasculature, cells, nanoparticles, and drug molecules is a
complex kinetic process in need of further consideration not only in experimental work but
also in future computational modeling and simulation studies. Recently, a vascularized
tumor model system was proposed that considers the differences in drug kinetics among
various cellular compartments (Curtis, van Berkel et al. 2018). Further studies could
combine drug kinetics with a nanoparticle delivery model. The model used herein simulates
cell death as an instantaneous process. However, cell cycle dependent drugs such as
cisplatin rely on apoptosis and may take several hours before cytotoxic effects are realized
(Siddik 2003). Thus, another consideration for future work is to account for the delay in
the drug cytotoxic action. Additionally, there are several well characterized drug resistance
mechanisms such as decreased intracellular transport, enzymatic deactivation, and
alteration in proteins involved in apoptotic pathways (Stewart 2007).These mechanisms
could be integrated to create more comprehensive pharmacodynamics models.

29

REFERENCES
Bertrand, N., et al. (2014). "Cancer nanotechnology: the impact of passive and active
targeting in the era of modern cancer biology." Adv Drug Deliv Rev 66: 2-25.
Brahimi-Horn, M. C. and J. Pouyssegur (2005). "The hypoxia-inducible factor and tumor
progression along the angiogenic pathway." Int Rev Cytol 242: 157-213.
Chamseddine, I. M., et al. (2018). "Design Optimization of Tumor Vasculature-Bound
Nanoparticles." Scientifc Reports (in press).
Chen, H., et al. (2017). "Quantification of Tumor Vascular Permeability and Blood Volume
by Positron Emission Tomography." Theranostics 7(9): 2363-2376.
Curtis, L. T., et al. (2016). "An interdisciplinary computational/experimental approach to
evaluate drug-loaded gold nanoparticle tumor cytotoxicity." Nanomedicine (Lond) 11(3):
197-216.
Curtis, L. T., et al. (2016). "A Computational/Experimental Assessment of Antitumor
Activity of Polymer Nanoassemblies for pH-Controlled Drug Delivery to Primary and
Metastatic Tumors." Pharm Res.
Curtis, L. T., et al. (2018). "Pharmacokinetic/pharmacodynamic modeling of combinationchemotherapy for lung cancer." J Theor Biol 448: 38-52.
Curtis, L. T., et al. (2015). "Computational Modeling of Tumor Response to Drug Release
from Vasculature-Bound Nanoparticles." PLoS One 10(12): e0144888.
Decuzzi, P., et al. (2009). "Intravascular delivery of particulate systems: does geometry
really matter?" Pharm Res 26(1): 235-243.

30

England, C. G., et al. (2015). "Evaluation of uptake and distribution of gold nanoparticles
in solid tumors." Eur Phys J Plus 130(11).
England, C. G., et al. (2015). "Detection of Phosphatidylcholine-Coated Gold
Nanoparticles in Orthotopic Pancreatic Adenocarcinoma using Hyperspectral Imaging."
PLoS One 10(6).
England, C. G., Huang, J.,S. James K.T., Zhang, X., Gobin, A.M., Frieboes, H.B. (2015).
"Detection of Phosphatidylcholine-Coated Gold Nanoparticles in Orthotopic Pancreatic
Adenocarcinoma using Hyperspectral Imaging." PLoS One 10(6): e0129172.
England, C. G., Miller, M.C., Kuttan, A., Trent, J.O., Frieboes, H.B. (2015). "Release
Kinetics of Paclitaxel and Cisplatin from Two and Three Layered Gold Nanoparticles."
Eur J Pharm Biopharm 92: 120-129.
England, C. G., et al. (2013). "Enhanced penetration into 3D cell culture using two and
three layered gold nanoparticles." Int J Nanomedicine 8: 3603-3617.
Frens, G. (1973). "Controlled Nucleation for the Regulation of the Particle Size in
Monodisperse Gold Solutions." Nature Physical Sciences 241: 20-22.
Frieboes, H. B., et al. (2006). Nanotechnology in Cancer Drug Therapy: A
Biocomputational Approach. BioMEMS and Biomedical Nanotechnology. M. Ferrari, A.
P. Lee and L. J. Lee. New York, Springer-Verlag: 435-460.
Frieboes, H. B., et al. (2013). "A computational model for predicting nanoparticle
accumulation in tumor vasculature." PLoS One 8(2): e56876.
Gao, Y., et al. (2013). "Predictive models of diffusive nanoparticle transport in 3dimensional tumor cell spheroids." AAPS J 15(3): 816-831.
Godin, B., et al. (2010). "An integrated approach for the rational design of nanovectors for
biomedical imaging and therapy." Adv Genet 69: 31-64.
Hait, W. N. and T. W. Hambley (2009). "Targeted cancer therapeutics." Cancer Res 69(4):
1263-1267.
31

Hall, R. D., et al. (2015). "Angiogenesis inhibition as a therapeutic strategy in non-small
cell lung cancer (NSCLC)." Translational Lung Cancer Research 4(5): 515-523.
Izuishi, K., et al. (2000). "Remarkable tolerance of tumor cells to nutrient deprivation:
possible new biochemical target for cancer therapy." Cancer Res 60(21): 6201-6207.
Jain, R. K. (2001). "Normalizing tumor vasculature with anti-angiogenic therapy: a new
paradigm for combination therapy." Nature Medicine 7(9): 987-989.
Kaddi, C. D., et al. (2013). "Computational nanomedicine: modeling of nanoparticlemediated hyperthermal cancer therapy." Nanomedicine (Lond) 8(8): 1323-1333.
Koziara, J. M., et al. (2006). "In-vivo efficacy of novel paclitaxel nanoparticles in
paclitaxel-resistant human colorectal tumors." J Control Release 112(3): 312-319.
Leighl, N. B. (2012). "Treatment paradigms for patients with metastatic non-small-cell
lung cancer: first-, second-, and third-line." Curr Oncol 19(Suppl 1): S52-58.
Li, M., et al. (2010). "Physiologically based pharmacokinetic modeling of nanoparticles."
Acs Nano 4(11): 6303-6317.
Li, M., et al. (2013). "Delineating intracellular pharmacokinetics of paclitaxel delivered by
PLGA nanoparticles." Drug Deliv Transl Res 3(6): 551-561.
Li, M., et al. (2012). "Physiologically based pharmacokinetic modeling of PLGA
nanoparticles with varied mPEG content." Int J Nanomedicine 7: 1345-1356.
Li, M. and J. Reineke (2011). "Mathematical modelling of nanoparticle biodistribution:
extrapolation among intravenous, oral and pulmonary administration routes." Int J Nano
Biomaterials 3(3): 222-238.
Ma, E., et al. (2016). "ROI for outlining an entire tumor is a reliable approach for
quantification of lung cancer tumor vascular parameters using CT perfusion." Oncotargets
and Therapy 9: 2377-2384.
32

Macklin, P., et al. (2009). "Multiscale modelling and nonlinear simulation of vascular
tumour growth." J Math Biol 58(4-5): 765-798.
McDougall, S. R., et al. (2006). "Mathematical modelling of dynamic adaptive tumourinduced angiogenesis: clinical implications and therapeutic targeting strategies." J Theor
Biol 241(3): 564-589.
Miele, E., et al. (2012). "Nanoparticle-based delivery of small interfering RNA: challenges
for cancer therapy." Int J Nanomedicine 7: 3637-3657.
Minchinton, A. I. and I. F. Tannock (2006). "Drug penetration in solid tumours." Nat Rev
Cancer 6(8): 583-592.
Nugent, L. J. and R. K. Jain (1984). "Extravascular diffusion in normal and neoplastic
tissues." Cancer Res 44(1): 238-244.
Primeau, A. J., et al. (2005). "The Distribution of the Anticancer Drug Doxorubicin in
Relation to Blood Vessels in Solid Tumors." Clinical Cancer Research 11(24): 8782-8788.
Reichel, D., et al. (2017). "Development of Halofluorochromic Polymer Nanoassemblies
for the Potential Detection of Liver Metastatic Colorectal Cancer Tumors Using
Experimental and Computational Approaches." Pharm Res 34(11): 2385-2402.
Siddik, Z. H. (2003). "Cisplatin: mode of cytotoxic action and molecular basis of
resistance." Oncogene 22(47): 7265-7279.
Stewart, D. J. (2007). "Mechanisms of resistance to cisplatin and carboplatin." Crit Rev
Oncol Hematol 63(1): 12-31.
van de Ven, A. L., et al. (2013). "Modeling of nanotherapeutics delivery based on tumor
perfusion." New Journal of Physics 15.
van de Ven, A. L., et al. (2012). "Integrated intravital microscopy and mathematical
modeling to optimize nanotherapeutics delivery to tumors." AIP Adv 2(1): 11208.

33

Warren, K. E. (2013). "Novel therapeutic delivery approaches in development for pediatric
gliomas." CNS Oncol 2(5): 427-435.
Wu, M., et al. (2014). "The effect of interstitial pressure on therapeutic agent transport:
coupling with the tumor blood and lymphatic vascular systems." J Theor Biol 355: 194207.
Wu, M., et al. (2014). "The effect of interstitial pressure on therapeutic agent transport:
Coupling with the tumor blood and lymphatic vascular systems." Journal of Theoretical
Biology 355: 194-207.
Wu, M., et al. (2013). "The effect of interstitial pressure on tumor growth: Coupling with
the blood and lymphatic vascular systems." J Theor Biol 320: 131-151.
Zhong, H., et al. (1999). "Overexpression of hypoxia-inducible factor 1alpha in common
human cancers and their metastases." Cancer Res 59(22): 5830-5835.

34

CURRICULUM VITAE
NAME:

Hunter Allan Miller

ADDRESS:

Department of Pharmacology and Toxicology
505 S Hancock St.
University of Louisville School of Medicine
Louisville, KY 40202

EDUCATION &
TRAINING:

B.S. Chemistry/Biochemistry
Murray State University
2011-2016

PUBLICATIONS:
HA Miller, HB Frieboes. Evaluation of Cancer Nanotherapy as a Function of Tumor
Vascularization. Presentation at Biomedical Engineering Society annual meeting Atlanta,
GA (Oct. 2018)
HA Miller, HB Frieboes. Evaluation of drug-loaded gold nanoparticle cytotoxicity as a
function of tumor tissue heterogeneity. Annals of Biomedical Engineering 2018 (in
review)
LB Sims*, HA Miller*, ME Halwes, JM Steinbach-Rankins, HB Frieboes. Modeling of
nanoparticle transport through the vaginal epithelium for the treatment of infectious
diseases. Eur J Pharmacol Pharmaceutics 2018 (in review). *Joint first authorship
HA Miller, HB Frieboes. Simulation of the effect of tumor vessel density on drug loaded
gold nanoparticle efficacy. Poster presentation at Research Louisville (2017)

35

